This complex scenario highlights an ambiguous role of DUSPs that can act as oncosuppressors or oncogenic molecules, depending on the tumor type, the timing of ERK activation, the presence of additional oncogenic mutations in the RAS/RAF/ERK axis [73]. Here, MAPK1 is linked to neoplasm.